Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-804-9 | CAS number: 99-96-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- toxicity to reproduction
- Remarks:
- other: screening
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well-documented study which meets basic scientific principles
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 997
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- yes
- Remarks:
- : duration, number of animals, dosages, administration volume, hematology, clinical chemistry, organ weights, histopathologic examination, neurobehaviour
- Principles of method if other than guideline:
- 13 animals per each sex and dose group were treated (whereas OECD 422 recommends that each group is started with at least 10 animals of each sex)
- GLP compliance:
- not specified
Test material
- Reference substance name:
- 4-hydroxybenzoic acid
- EC Number:
- 202-804-9
- EC Name:
- 4-hydroxybenzoic acid
- Cas Number:
- 99-96-7
- Molecular formula:
- C7H6O3
- IUPAC Name:
- 4-hydroxybenzoic acid
- Details on test material:
- - Name of test material: 4-hydroxybenzoic acid
- Physical state: solid, white crystalline powder
- Analytical purity: 99.7%
- Impurities (identity and concentrations): 0.02 (w/w)% salicylic acid, 0.03 (w/w)% 4-hydroxyisophthalic acid
- Lot/batch No.: GI0681
- supplier: Ueno Seikyku Co., LTD.
- Storage condition of test material: room temperature
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Sprague-Dawley Crj:CD, SPF
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Nippon Charles River Co., Ltd., Hino Rearing Center
- Age at purchase: 7 weeks
- weight rage at time of grouping: males 305.3 - 348.0 g, females 206.6 - 233.9 g
- Fasting period before study: no
- Housing: individually in metal cages with mesh floor (22 x 27 x 19 cm³) in a rearing room
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: one week
- Sex: male, female
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24 +/- 1
- Humidity (%): 50-65
- Air changes (per hr): 15 times
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
VEHICLE: suspension in water
- Concentration in vehicle: 0.5% Carboxymethyl Cellulose Sodium (CMC), Maruishi Seiyaku Co. Ltd., Production No. 1527),
Japan Pharmacopeia injection-quality water, Hikari Seiyaku Co. Ltd., Production No. 9510AH
- Amount of vehicle: 5 ml/kg - Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1/1 (probably) (male animals: see Endpoint study record in section 7.5.1 "Repeated dose Toxicity")
- Length of cohabitation: until copulation/ up to 14 days
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: vaginal plug / sperm in vaginal smear referred to as day 0 of pregnancy - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- males: 42 administrations, (2 weeks before mating, 2 weeks during mating and 2 weeks after mating period)
females: in total up to 52 days: 14 days pre-mating period and up to 14 days mating period (until copulation), through the pregnancy period (assuming 20 days pregnancy) until lactation day 3 after delivery (4 days lactation period) - Frequency of treatment:
- daily by stomach tube
- Details on study schedule:
- - Age at mating of the mated animals in the study: 10 weeks
Doses / concentrations
- Remarks:
- Doses / Concentrations:
actual ingested doses were based on the weekly measured body weights/ body weight at the beginning of the pregnancy
Basis:
actual ingested
0, 40, 200, 1000 mg/kg bw./day
- No. of animals per sex per dose:
- 13
- Control animals:
- yes
- Details on study design:
- - Control groups: aqueous solution of 0.5% CMC Na
- Dose selection rationale:
Results of a pilot study with 14-days repeated oral administration to male and female rats:
250 mg/kg bw : salivation, abnormal respiratory sounds, rhinorrhea
females: reduced body weight gain
1000 mg/kg bw: salivation, abnormal respiratory sounds, rhinorrhea, reduced body weight gain,
females: reduced: food consumption
- Rationale for animal assignment: ramdomly grouped
- Section schedule rationale: all animals werde sacrificed - Positive control:
- no
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations:
males: on administration days 1,8,15,22,29,36,42 and on the day of autopsy,
females: on administration days 1, 8 and 15, on day 22 for females that did not copulate until day 22, postcopulation females: pregnancy days 0, 7, 14, 20 and postpartum females: on lactation days 0 and 4
(administration day 1 = first day of study), - Sperm parameters (parental animals):
- Parameters examined in male parental generations: testis weight, epididymis weight, histopathology of testis and epidymidis
- Litter observations:
- PARAMETERS EXAMINED
numbers of pups born, delivery index, number of pups alive, birth index, live birth index, pup weight on day 0 of lactation, sex ratio, number of pups alive on day 4 of lactation, viability index, pup weight on day 4 of lactation, general status of pups, observation of external deformities
GROSS EXAMINATION OF DEAD PUPS: yes, for external and internal abnormalities - Postmortem examinations (parental animals):
- POST-MORTEM EXAMINATIONS: Yes
SACRIFICE
- Male animals after 42 days: All surviving animals
- Female animals: Sacrifice on lactation day 4 (starting with day 0), on the last day of mating period for females that did not copulate, and on the equivalent of pregnancy day 25 for females for which copulation was confirmedbut which did not deliver.
ORGAN WEIGHTS
- Liver, kidneys, lung, thymus, testes, epididymis.
ORGANS FIXED:
- liver, kidneys, lung, thymus, testes, epididymis, brain, heart, spleen, adrenals, uterus, and bladder
HISTOPATHOLOGY (high dose and control animals):
- Liver, heart, thymus, kidney, urinary bladder, lung, spleen, testis, and epididymis - Postmortem examinations (offspring):
- HISTOPATHOLOGY
The organs in the thoracic and abdominal cavities were excised together and were fixed in 10% formalin and preserved according to litter. The carcasses were fixed in ethanol and preserved according to litter. - Statistics:
- Mean graded data for histopathological findings were tested for significant differences between the control and various dosage groups using Mann-Whitney's U-test, and positive grade totals using Fisher's direct probability one-tailed test. For all other data, which values obtained for individuals the uniformity of distribution of the various groups was first tested by Bartlett's method. When this resulted in a uniform distribution, a one-dimensional distribution analysis was performed, and when intergroup significance was observed, the differences in the mean values between the control and various dosage groups were tested using Dunnett's method if the number of animals per group was the same, or Scheffé's method when it was not. When the distribution was not uniform or when there were groups for which the distribution was 0, the Kruskal-Wallis rank sum test was performed. When intergroup significance was observed, Dunnett's or Scheffé's method tests the differences between the control and various dosage groups were performed. The level of significance was 5% or 1%.
- Reproductive indices:
- number of mated pairs, number of copulated pairs, copulation index, number of pregnant animals, fertility index, pairing days until copulation, frequency of vaginal estrus, number of pregnant females, number of pregnant females with pups alive, gestation index, gestation lenth in days, number of corpora lutea, number of imlantation sites, implantation index, number of pups born, delivery index
- Offspring viability indices:
- number of pups alive, birth index, live birth index, pup weight on day 0 of lactation, sex ratio, number of pups alive on day 4 of lactation, viability index, pup weight on day 4 of lactation, general status of pups, observation of external deformities
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- With doses 200 mg/kg bw. and above abnormal respiratory sounds or transient post-administration salivation
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- suppressed weight gain in males with doses of 1000 mg/kg bw./day
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- With doses 200 mg/kg bw. and above reduced lymophocyte ratio was abserved
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In males with doses of 200 mg/kg bw and above reduced glucose was observed.
With dose of 1000 mg/kg bw. reduced total protein and elevated GPT, GOT and increased A/G ratio was observed. - Endocrine findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not examined
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
Details on results (P0)
NOEL: 40 mg/kg bw.
200 mg/kg bw: transient post-administration salivation, abnormal respiratory sounds, Hematology/Clinical chemistry: males reduced lymphocyte ratio and reduced glucose level ,
-1000 mg/kg bw: Clinical signs: salivation, rhinorhea, abnormal respiratory sounds, males reduced: body weight gain, Hematology/Clinical Chemistry: reduced: white blood cell count, platelet count, total serum protein, increased: segmented neutrophil ratio, GPT, GOT, inorganic phosphorus.
The following significant differences were seen as merely statistical effects caused by the biological variation and not based on a test item related biological effect:
40 mg/kg bw.: reduced: glucose and white blood cell count, increased: ratio of eosinophil ,
200 mg/kg bw.: reduced: glucose, increased: blood calcium,
1000mg/kg bw.: reduced: white blood cell count and glucose, increased A/G-40 mg/kg bw: no observable effects
FEMALE ANIMALS:
NOEL: 40 mg/kg bw
-200 mg/kg bw: abnormal respiratory sounds: 3 animals 1-2 times
-1000 mg/kg bw: salivation: 13 animals 2-23 times, rhinorhea: 1 animal 1time, abnormal respiratory sounds: 9 animals 1-10 times, lungs: inflamatory foci (1 in the control group, 4 cases in the dosage group)
Effect levels (P0)
open allclose all
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- > 200 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- mortality
- body weight and weight gain
- food consumption and compound intake
- haematology
- clinical biochemistry
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 40 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- haematology
- clinical biochemistry
- Key result
- Dose descriptor:
- NOEL
- Remarks:
- reproductive/developmental toxicity
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- mortality
- body weight and weight gain
- food consumption and compound intake
- haematology
- clinical biochemistry
- urinalysis
- organ weights and organ / body weight ratios
- gross pathology
- reproductive performance
- Remarks on result:
- other: Generation: P and F1 (migrated information)
Target system / organ toxicity (P0)
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 200 mg/kg bw/day (nominal)
- System:
- respiratory system: upper respiratory tract
- Organ:
- blood
- nasal cavity
- oral cavity
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- presumably yes
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Anogenital distance (AGD):
- not examined
- Nipple retention in male pups:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not examined
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not examined
Details on results (F1)
BODY WEIGHT (OFFSPRING): no significant differences between the control group and the various dosage groups werde observed in males or females in body weights on day 0 or lactation day 4.
GROSS PATHOLOGY (OFFSPRING): no external deformities were observed in the surviving pups on the day of birth. In autopsies of pups on lactation day 4, no abnormalities were observed in the control, nor were any abnormalities in the autopsy of the dead pup.
Effect levels (F1)
- Key result
- Dose descriptor:
- NOEL
- Generation:
- F1
- Effect level:
- > 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- viability
- clinical signs
- mortality
- gross pathology
Target system / organ toxicity (F1)
- Key result
- Critical effects observed:
- no
Overall reproductive toxicity
- Key result
- Reproductive effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Daily dosages of 0, 40, 200, and 1000 mg/kg bw./day were administred by stomach tube to groups of 13 male and female rats for a 14 days pre-mating period, for a mating period up to 14 days. The administration to the males was continued for 2 further weeks, totally 42 days. The administration to the females was continued for the pregnancy period of 20 days and for a lactation period of 4 days. All in all between 38 to 52 days (depending on the mating period). The test-article was formulated in 0.5%CMC, the administration volume was 5 ml/kg bw.
NOEL = 40 mg/kg bw.,
NOEL for Repeated dose toxicity: 40 mg/kg bw./day,
NOEL for Reproductive toxicity: 1000 mg/kg bw./day,
NOEL for Developmental toxicity: 1000 mg/kg bw./day,
Pups: NOEL: 1000 mg/kg bw/day. - Executive summary:
Daily dosages of 0, 40, 200, and 1000 mg/kg bw./day were administred by stomach tube to groups of 13 male and female rats for a 14 days pre-mating period, for a mating period up to 14 days. Whereas OECD 422 recommends that each group is started with at least 10 animals of each sex. The administration to the males was continued for 2 further weeks, totally 42 days. The administration to the females was continued for the pregnancy period of 20 days and for a lactation period of 4 days. All in all between 38 to 52 days (depending on the mating period). The test-article was formulated in 0.5%CMC, the administration volume was 5 ml/kg bw.
NOEL = 40 mg/kg bw..
200 mg/kg bw./day lead to abnormal respiratory sounds and additionally with the male animals to salivation and reduced lymphocyte ratio and platelet count.
1000 mg/kg bw: salivation, abnormal respiratory sound, rhinorhea, males: reduced body weight gain, white blood cell count, platelet count, total serum protein, increased: segmented neutrophil ratio, GPT, GOT, inorganic phosphorus, females: lung: inflamatory foci.
- NOEL for Repeated dose toxicity: 40 mg/kg bw./day
- NOEL for Reproductive toxicity: 1000 mg/kg bw./day
- NOEL for Developmental toxicity: 1000 mg/kg bw./day
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.